Clinical trial
A randomized, double blind, two arm, parallel, placebo controlled study of rimonabant 20mg effect on high density lipoprotein kinetics in patients with abdominal obesity and additional cardiometabolic risk factors
The Primary End-point is the fractional catabolic rate of ApoA-I in HDL after 12 months of treatment.
| Category | Value |
|---|---|
| Study start date | 2006-12-29 |